Platelet-activating factor (PAF) has been shown to play a critical role in mediating vascular hyperpermeability during anaphylaxis. Although epinephrine is the first-line treatment for anaphylaxis and can inhibit increased vascular permeability during anaphylaxis, the effect of epinephrine on PAF-induced vascular hyperpermeability is still unclear. In this study, we investigated whether epinephrine can reduce vascular permeability and alleviate anaphylactic symptoms induced by PAF. We tested vascular permeability in vivo by measuring the Evans blue dye leakage and in vitro by transendothelial electrical resistance measurement. Blood pressure was measured with a noninvasive monitoring system. Body temperature was recorded using an electronic thermometer. Confocal microscopy was used to characterize gap areas of human umbilical vein endothelial cells (HUVECs). Phosphorylation of VEcadherin was assessed using western blot. 
Introduction
Anaphylaxis is a serious, potentially fatal, systemic hypersensitivity reaction, which is characterized by cutaneous manifestations and acute respiratory and cardiovascular compromise (laryngeal edema, hypotension and vascular leakage).
1 The presence of respiratory or cardiovascular symptoms is a sign of life-threatening anaphylaxis.
2 Within the rst 10 minutes of anaphylaxis, vascular hyperpermeability can rapidly transfer up to 35% of the intravascular uid into the extravascular space, which leads to hemodynamic collapse and laryngeal obstruction and exacerbates anaphylactic symptoms.
3-5
During anaphylaxis, several pro-inammatory mediators are released into the bloodstream, among which platelet-activating factor (PAF), histamine, and TNF-alpha have been shown to increase vascular permeability.
6-8 PAF, also known as 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine, acetyl-glyceryl-etherphosphorylcholine (AGEPC), or PAF-acether, has been proposed to be the most powerful phospholipid-derived mediator (Fig. 1A) . 9 It has been shown to be effective at concentrations as low as 10 À12 mol L À1 , a thousand times lower than that of histamine. 9 PAF receptor antagonists that inhibit PAF binding to its receptor can substantially reduce the increased vascular leakage in peanut-sensitized animals. 10 In ovalbumin (OVA)-sensitized mice, PAF, rather than histamine, is involved in mouse anaphylactic hypotension.
11 PAFR-knockout mice showed less severe hypotension and higher survival rates than wild-type mice. 12 Clinical research showed that serum PAF levels were directly correlated with the severity of anaphylaxis.
1
Compared with serum tryptase or histamine levels, high PAF levels are better correlated with severe anaphylaxis. 13 These animal and human data support the prominent role of PAF in the pathogenesis of anaphylaxis and vascular hyperpermeability.
Epinephrine is a life-saving agent in treating fatal anaphylaxis (Fig. 1B) . 2, 14, 15 Epinephrine rescues patients with anaphylaxis through multiple pharmacological effects, including peripheral vasoconstriction effects via a 1 adrenergic receptors, rate and force increases in cardiac contractions via b 1 adrenergic receptors, bronchodilation and inhibition of histamine release from mast cells via b 2 adrenergic receptors. 16 However, the effect of epinephrine in inhibiting PAF-induced vascular hyperpermeability has not been investigated.
Transcellular and paracellular pathways regulate vascular permeability, and paracellular pathways play an important role in the rapid pathophysiological development of anaphylaxis. 17 The paracellular permeability of the endothelium is regulated by the interendothelial junctions, including adherens junctions (AJs) and tight junctions (TJs). VE-cadherin is believed to play a prominent role in AJ integrity. 18, 19 On the one hand, PAF can induce endothelial barrier disruption by breaking the interendothelial junctions, especially the VEcadherin connection between adjacent vascular endothelial cells. 6 On the other hand, an increase in cAMP level in endothelial cells promotes protective barrier function and attenuates endothelial permeability, resulting in decreased vascular leakage.
20-22
The beta-adrenergic activationstimulated cAMP-Epac-Rap1 signal pathway enhanced VEcadherin-dependent cell adhesion.
23
Epinephrine can contribute to maintain the baseline endothelial barrier via increasing cAMP levels by stimulating b adrenergic receptors on endothelial cells. 22 However, whether epinephrine can inhibit the PAF-induced endothelial barrier disruption is still unclear.
Thus, the objective of this study was to investigate the protective effect of epinephrine on vascular permeability following PAF-or OVA-induced anaphylaxis in vivo and to explore the effect of epinephrine on endothelial barrier function under PAF challenge in human umbilical vein endothelial cells (HUVECs).
Materials and methods

Reagents and antibodies
Reagents and antibodies PAF (Cat: #P4904), Evans blue dye (Cat: #E2129), and aluminum potassium sulfate adjuvant (Cat: #A6435) were obtained from Sigma-Aldrich (St. Louis, MO, USA); OVA (Cat: #vac-pova-100) was from InvivoGen (San Diego, CA, USA). Epinephrine was purchased from Shanghai Harvest Pharmaceutical Co., Ltd. (Shanghai, China); Darapladib (Cat: #HY-10521) was from Medchem Eexpress (Monmouth junction, NJ, USA). The enzyme-linked immunosorbent assay (ELISA) kit for PAF was purchased from Keboshengchuang Biotechnology (Beijing, China), and VascuLife VEGF Cell Culture Medium was purchased from Lifeline Cell Technology (Frederick, MD, USA). Rabbit anti-phospho-VE-cadherin (Tyr658) antibody (Cat #: 44-1144G) was from Invitrogen (Carlsbad, CA, USA); rabbit antiphospho-VE-cadherin (Tyr 685) antibody (Cat #: ab 119785) was from Abcam (Cambridge, MA, USA); rabbit anti-phospho-VE-cadherin (Tyr 731) antibody (Cat #: SAB4504676) was from Sigma-Aldrich; rabbit anti-VE-cadherin antibody (Cat: #2500s) was from Cell Signaling Technology (Danvers, MA, USA) and mouse anti-b-actin antibody (Cat: #A5441) was from SigmaAldrich (St. Louis, MO, USA); Alexa Fluor 555-labeled goat anti-rabbit IgG secondary antibody (Cat: #A21430) and Hoechst 33342 (Cat: #62249) were obtained from Thermo Fisher (Rockford, IL, USA); and Alexa Fluor 488-labeled rhodaminephalloidin (Cat: #PHDG1) was from Cytoskeleton (Denver, CO, USA).
Animals
Male BALB/c mice (10-12 weeks old and 25.0 AE 2.0 g) were purchased from Beijing Wei Tong Li Hua Experimental Animal Technology Co., Ltd. (Beijing, China) with the certicate number SCXK (Beijing) 2012-0001. The mice were housed in a specic pathogen-free (SPF) environment at 24 C under a 12 hour/12 hours light-dark cycle. Mice were given ad libitum access to a normal diet and water. In the PAF-induced anaphylaxis model, male BALB/c mice were randomly divided into the control, PAF or PAF + EPI groups for vascular permeability and hematocrit measurements (n ¼ 18), blood pressure and body temperature measurements (n ¼ 18), survival rate and ear thickness measurements (n ¼ 48) and determination of brain blood supply (n ¼ 18). In the OVA-induced anaphylaxis model, male BALB/c mice (n ¼ 54) were randomly divided into the control, OVA or OVA + EPI groups. The experimental protocol for the model and measurement methods are described below. 24 The dose of epinephrine was selected according to the veterinary formulary on the website of research animal resources of the University of Minnesota.
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Body temperature and blood pressure were monitored every 10 minutes until 60 minutes aer the challenge.
Alternatively, anaphylaxis was induced via OVA with twoweek duration. 26 Mice were sensitized with 0.1 mg of OVA and 2 mg of aluminum potassium sulfate adjuvant dissolved in 200 mL of physiologic saline via subcutaneous injection. The antigen was injected twice at a one-week interval. Nonsensitized mice were injected with aluminum potassium sulfate and OVAfree saline (i.v.). At 2 weeks aer the rst injection, mice were challenged by i.v. OVA through the tail vein. The OVA model group and nonsensitized mice were both challenged with OVA (0.1 mg in 200 mL of physiologic saline), and the epinephrine intervention group was injected with epinephrine (100 mg kg body wt À1 in 200 mL of physiologic saline, i.v.) immediately aer 0.1 mg OVA injection. Body temperature, ear thickness, and hematocrit of mice were monitored at 15, 30, and 60 minute time points aer OVA challenge, and plasma PAF levels were measured 15 minutes aer OVA challenge. The ear thickness was measured using digital caliper. The detailed methods were described as below. Mice were euthanized with CO 2 1 hour aer OVA challenge.
Vascular permeability and hematocrit measurements
In the PAF-induced anaphylaxis model, mice were injected with PAF in 0.5% Evans blue dye solution diluted in 200 mL physiologic saline (i.v.). Ten minutes later, the mouse ears were photographed by 5 megapixel camera with a 3.85 mm f/2.8 lens, and mice were anesthetized with ketamine (100 mg kg body wt À1 ) and xylazine (2.5 mg kg body wt À1 ). Blood samples were obtained from the right ventricle to determine hematocrit. The ears were removed, and the ear weight was determined. Aer ears were dried at 60 C overnight, ear tissues were sonicated in 0.5 mL formamide for 30 seconds. Four days later, the Evans blue in formamide extract was measured as OD 620 nm .
27
Blood pressure and body temperature measurements Nonanesthetized mice were used to simulate realistic conditions. Mice were trained in three days, 15 minutes each day, before beginning blood pressure measurement, so that they were accustomed to being restrained in the holder. Systolic and diastolic blood pressure was measured using a volume-pressure recording noninvasive blood pressure monitoring system (CODA, Kent Scientic, Torrington, CT, USA). Blood pressure was measured at baseline and every 10 minutes for 1 hour aer challenge. Rectal body temperature was recorded using an electronic thermometer (HI 98509, Hanna instrument, Woonsocket, RI, USA) at baseline and every 10 minutes for 1 hour aer challenge. Mice were euthanized with CO 2 aer blood pressure and body temperature measurements.
Survival rate and ear thickness measurements
In survival experiments, mice were intravenously injected with PAF (80 mg kg body wt À1 ) alone or PAF (80 mg kg body wt À1 ) with epinephrine (100 mg kg body wt À1 ) simultaneously or epinephrine 1, 5, and 10 minutes aer PAF injection. The PAF dose for the survival experiment was selected according to a previously published paper. 24 The survival rate was monitored every 10 minutes until 120 minutes aer challenge, and then mice were euthanized with CO 2 . The thickness of both ears was measured using digital caliper (0-200 mm, blue light machinery and electricity instrument, Beijing, China) on the day before intervention. Thirty minutes later, aer the injection of PAF or when the mice were dead within 30 minutes aer injection, the thickness of both ears was measured.
Determination of brain blood supply by laser doppler line scanner (LDLS)
In the PAF-induced anaphylaxis model, mice were administered intravenously with PAF (40 mg kg body wt À1 ) with/without epinephrine (100 mg kg body wt À1 ) through the tail vein.
Then, mice were anesthetized by an intraperitoneal injection of ketamine (100 mg kg body wt À1 ) with xylazine (2.5 mg kg body wt À1 ). The scalp was incised aer mice received anesthesia. The brain blood supply was measured by LDLS (Moor Instruments Ltd, UK) 10, 20, 30, and 60 minutes aer the challenge. The mode of image scan measurement was used. The blood ow image is in the range of 0 to 600 ux units.
Determination of PAF levels
Considering the release of PAF occurs within minutes in the early stages of anaphylaxis, 28 plasma PAF level 15 minutes aer OVA challenge was measured by an ELISA kit according to the manufacturer's protocol. Given the unstable characteristics of PAF in the blood sample due to degradation by PAF acetylhydrolase, the PAF-AH inhibitor Darapladib (20 mL of 100 nM Darapladib in 50 mg mL À1 EDTA) was added to 300 mL blood samples and gently mixed. Samples were centrifuged for 15 minutes at 1000 Â g at 4 C within 30 minutes of collection. The plasma was removed, and the assay was immediately performed using a microplate reader (Thermo Fisher Scientic Waltham, MA, USA) at a wavelength of 450 nm.
Cell lines and cell culture
HUVECs were obtained from Lifeline Cell Technology (Frederick, MD, USA). The cells were incubated in VascuLife VEGF Cell Culture Medium plus 2% (v/v) heat-inactivated fetal calf serum at 37 C with 5% CO 2 and 95% air in a humidied atmosphere and used between passages 2 to 8. Passages 4 and 6 of HUVECs were used for trans-endothelial electrical resistance junction permeability assay and immunouorescence. Passages 7 and 8 of HUVECs were used for Western blot.
Trans-endothelial electrical resistance (TER) junction permeability assay
An electrical cell-substrate impedance system (ECIS 1600R, Applied BioPhysics Inc., NY, USA) was used to measure the TER of endothelial junction integrity. First, 5 Â 10 4 HUVECs were seeded in gelatin-coated 8-well arrays (Cat #: 8 W10E+, Applied BioPhysics) and reached conuence in three days. Aer the HUVECs were serum starved for two hours, the resistance between the baseline and 1.5 hours post PAF (2 mM) with/ without epinephrine (10 mM) was measured by ECIS 1600R. The dose of PAF and epinephrine was selected according to published papers. were seeded in a 96-well plate and incubated for 2 days to achieve 90-100% conuence. HUVECs were challenged with 2 mM PAF with/without 10 mM epinephrine for 10 minutes. Aer stimulation, HUVECs were xed and permeabilized as described in Mikelis' method. 7 Then, HUVECs were stained with Alexa Fluor 488-labeled rhodamine-phalloidin for 2 hours at 37 C and stained with Hoechst 33342 (1 : 1000) for 5 minutes at 37 C. During acquisition, 25 elds per well were randomly imaged using Â60 objective for the following channels: UV/blue for Hoechst nuclear stain, FITC/FITC for Alexa Fluor 488-labeled rhodamine-phalloidin. Data analysis was then performed via imaging analysis of the Operetta high-content imaging system (Operetta, PerkinElmer, Santa Clara, CA, USA).
Western blot
SDS-PAGE and western blotting were performed according to established protocols. 30, 31 HUVECs were treated with 2 mM PAF for 1, 5, and 15 minutes. Cells were lysed directly in culture dishes on ice by adding RIPA buffer containing 1% protease and phosphatase inhibitor cocktail (P8340, P5726, P0044, SigmaAldrich, St. Louis, MO, USA). The protein concentration was determined using a BCA protein assay (Cat: #23225, Thermo Fisher, Rockford, IL, USA). Thirty micrograms from each sample of lysed HUVECs was loaded into each well of 8% SDS-PAGE gels. Samples were separated by SDS-PAGE gels, transferred to nitrocellulose membranes, and immunoblotted with the following primary antibodies: rabbit anti-phospho-VEcadherin (Tyr658) antibody (1 : 500), rabbit anti-phospho-VEcadherin (Tyr 685) antibody (1 : 500), rabbit anti-phospho-VEcadherin (Tyr 731) antibody (1 : 500), rabbit anti-VE-cadherin antibody (1 : 3000) and mouse anti-b-actin antibody (1 : 5000).
Aer the incubation of primary antibody, membranes were washed with PBST and incubated with anti-rabbit (1 : 2500) or anti-mouse secondary antibody (1 : 2500). Blots were scanned as grayscale images and quantied using Quantity One soware (version 4.6.2, Hercules, CA, USA). The optical density of each band was quantied.
Statistics
All values are expressed as the mean AE SEM. Statistical comparisons of data between two groups were analyzed using the 2-tailed Student's t test, and comparisons between three or more groups were analyzed using one-way ANOVA, followed by a Newman-Keuls post hoc test. Two-way ANOVA was used to analyze differences between different challenges in the time course. A value of p < 0.05 was used to indicate a signicant difference.
Results
Epinephrine protects mice from vascular hyperpermeability in PAF-induced anaphylaxis
Aer injection of PAF, there was obvious inltration of blue dye into the skin tissue of the ears, forelimbs and eyelids ( Fig. 2A and B ). There was a more than threefold increase in Evans blue in the ear tissue of the PAF group compared with that in the control group (p < 0.001). Evans blue inltration in the ear tissue of the PAF + EPI group was signicantly less than that in the PAF group (p < 0.05). Ear thickness of the mice in the PAF group was signicantly larger than the thickness in the control group (p < 0.001, Fig. 2C ). Administration of epinephrine inhibited the increase in ear thickness in a timedependent manner. Simultaneously injecting epinephrine with PAF or injecting epinephrine 1 minute aer PAF injection signicantly suppressed ear thickness (p < 0.001). However, the effectiveness of epinephrine was decreased when epinephrine was injected 5 or 10 minutes aer PAF challenge.
To conrm that PAF can cause rapid transfer of intravascular uid into the extravascular space, we measured hematocrit levels 10 minutes aer PAF challenge. PAF-challenged mice showed higher hematocrit levels (p < 0.001), which could be inhibited by the administration of epinephrine (p < 0.001, Fig. 2D ).
Epinephrine attenuates PAF-induced anaphylactic symptoms
PAF can induce many anaphylactic symptoms, including dyspnea (Appendix Video 1 †), hypothermia, hypotension and even death. From 10 to 50 minutes aer PAF challenge, the rectal temperatures of the mice in the PAF group were signicantly lower than those in the control group (p < 0.001, p < 0.001, p < 0.001, p < 0.001, p < 0.05, respectively, Fig. 2E ). Ten minutes aer PAF challenge, the mean arterial blood pressures of the mice in the PAF group were dramatically lower than those in the control group (p < 0.01, Fig. 2F ). The administration of epinephrine effectively increased the rectal temperature from 10 to 40 minutes aer PAF challenge (p < 0.001, p < 0.001, p < 0.001, p < 0.001, Fig. 2E ) and increased mean arterial blood pressure at 10 minute intervals (p < 0.05, Fig. 2F ). Epinephrine time-dependently reduced the mortality rate caused by the injection of a lethal dose of PAF (80 mg kg body wt À1 ) (Fig. 2G ).
Both simultaneous injection of epinephrine and injection of epinephrine 1 minute aer PAF injection effectively increased the survival rate from 25% (3/12) to 100% (8/8). However, the delayed injection of epinephrine was less effective. The injection of epinephrine 5 or 10 minutes aer PAF injection only increased the survival rate to 87.5% (7/8) or 50% (4/8).
In preliminary experiments, we observed that the administration of lethal-dose PAF (i.v.) induced opisthotonus or generalized tonic symptoms lasting for 10 to 20 seconds (Appendix Video 2 †). We hypothesized that these manifestations were related to the low blood supply in the brain. Therefore, we tested the bloodstream volume of the brain by LDLS, which presents the blood perfusion volume of the brain as a deep blue to a deep red color ( Fig. 3A and B) . The blood supply of the brain was signicantly decreased at 10, 20, 30 and 60 minutes aer PAF challenge (p < 0.001, p < 0.001, p < 0.001, p < 0.01, respectively, Fig. 3C ). Simultaneous injection of epinephrine with PAF effectively inhibited the PAF-induced decrease in the brain blood supply at the 10, 20, 30 and 60 minute time points (p < 0.001, p < 0.01, p < 0.05, p < 0.05, respectively).
Epinephrine protects mice from vascular hyperpermeability and hypothermia in OVA-induced anaphylaxis OVA-induced active systemic anaphylaxis is a classical model for the investigation of systemic anaphylaxis. The protocol of OVA-induced active anaphylaxis is shown (Fig. 4A) . Ear thickness was signicantly augmented at 15, 30 and 60 minutes aer OVA stimulation (p < 0.001, p < 0.001, p < 0.001, respectively, Fig. 4B ). The injection of epinephrine effectively suppressed the ear swelling induced by OVA (p < 0.01, p < 0.001, p < 0.05, respectively, Fig. 4B ). Hematocrit levels were signicantly increased at the 15 minute time point and gradually decreased from 30 to 60 minutes aer OVA stimulation (p < 0.001, p < 0.01, p < 0.01, respectively, Fig. 4C ). Although it was not signicant, the average HCT levels in the OVA + EPI group were lower than those in the OVA group (Fig. 4C) . The PAF levels in the serum of mice with OVA-induced anaphylaxis were signicantly higher than those in the control group (p < 0.01, Fig. 4D ). The administration of epinephrine with OVA effectively reduced the elevated PAF level at the 15 minute time point aer OVA stimulation (p < 0.01, Fig. 4D ). Given that hypothermia serves as an important indicator of anaphylaxis in the OVA-induced active anaphylaxis model, we examined temperature change aer OVA stimulation. The data showed that OVA signicantly decreased body temperature 15, 30 and 60 minutes aer OVA challenge (p < 0.001, p < 0.001, p < 0.01, Fig. 4E ). The results indicated that epinephrine could signicantly attenuate OVA-induced ) with epinephrine (100 mg kg body wt À1 ) simultaneously or epinephrine 1, 5, and 10 minutes after PAF injection. EPI: epinephrine; HCT: hematocrit; MAP: mean arterial blood pressure. The data are presented as the mean AE SEM (n ¼ 6-12); *p < 0.05; **p < 0.01; ***p < 0.001, compared with the control group; #p < 0.05; ###p < 0.001, compared with the PAF group; if not marked, differences were not statistically significant.
hypothermia at 15 and 30 minute time points (p < 0.05, p < 0.05, respectively, Fig. 4E ).
Epinephrine protects HUVECs from PAF-induced severe endothelial barrier disruption
In conuent HUVEC monolayers, TER decreased to 73% of baseline levels (from 2138 AE 68 ohms to 1568 AE 125 ohms, n ¼ 3) aer 15 minutes of PAF incubation. TER increased to 118% of baseline levels (from 2177 AE 43 ohms to 2575 AE 41 ohms, n ¼ 3) aer 10 minutes of epinephrine incubation. The effect of PAF on the endothelial barrier was inhibited by co-incubation of epinephrine with PAF, resulting in values similar to baseline levels. As epinephrine acts faster than PAF, TER increased slightly and then decreased to baseline levels aer coincubation of epinephrine and PAF (Fig. 5A) . As shown in Fig. 5B , PAF induced disruption and disturbance of VEcadherin, which was inhibited by co-incubation of epinephrine with PAF (Fig. 5B, line 1 , PAF + EPI). When HUVECs were stimulated with PAF, we observed the formation of radial actin bundles (Fig. 5B line 2, PAF) . When HUVECs were stimulated with epinephrine and PAF, we observed the existence of more cytoplasmic bers scattered in the center of the HUVECs (Fig. 5B line 2, PAF + EPI) .
For the quantication of the change in gap areas, highcontent imaging screening was used. Incubation of PAF for 10 minutes disrupted the interendothelial junctions and signi-cantly increased the gap areas of conuent HUVECs (p < 0.001, Fig. 5C and D) . Co-incubation of epinephrine signicantly inhibited the PAF-induced increase in gap areas (p < 0.05, Fig. 5C and D) .
Several studies have reported that PAF can induce tyrosine phosphorylation of VE-cadherin and can promote its internalization, resulting in an increase in vascular permeability. 18 We rst reported that PAF induced the phosphorylation of Y658, Y685 and Y731 of VE-cadherin in HUVECs by using phosphorylation-specic antibodies (Fig. 6A) . In HUVECs, ) with/without epinephrine (100 mg kg body wt À1 ). Then, mice were anesthetized, and the brain blood supply was measured by LDLS at 10, 20, 30, and 60 minutes after challenge. (B) Image of a scalp incised after mice were anesthetized. (C) The bloodstream perfusion unit at 10, 20, 30, and 60 minutes after intravenous injection. EPI: epinephrine. The data are presented as the mean AE SEM (n ¼ 3-6); **p < 0.01; ***p < 0.001, compared with the control group; #p < 0.05; ##p < 0.01; ###p < 0.001, compared with the PAF group. If not marked, differences were not statistically significant. incubation with 2 mM PAF induced phosphorylation of VEcadherin at the Y658 residue aer 15 minutes (p < 0.01, Fig. 6B ), at the Y685 residue aer 1 minute (p < 0.05, Fig. 6C ) and at the Y731 residue at 1 and 5 minutes (p < 0.05, p < 0.01, respectively, Fig. 6D ). Whether epinephrine protects VEcadherin from phosphorylation by PAF remains to be answered.
Discussion
PAF is one of the most potent inammatory mediators that is responsible for anaphylactic symptoms. Traditionally, researchers have viewed OVA or bovine serum albumin (BSA) sensitization as a classical model of active systemic anaphylaxis. 32 In our study, we demonstrated that PAF (i.v.) induced similar anaphylactic symptoms to those exhibited in OVA-or BSA-induced models, including tissue edema, rapid and profound drops in body temperature and blood pressure, dyspnea and even death. Therefore, PAF-induced anaphylaxis may be a standard model for anaphylaxis. In addition, we demonstrated that increased vascular permeability plays an important role in the early stages of PAF-induced anaphylaxis. Using Evans blue, we observed that PAF can cause the rapid transfer of intravascular uid into the extravascular space in 10 minutes. By using a Doppler scanner, we observed that increased vascular permeability is responsible for hypoperfusion in the brain. The mice that died from PAF-induced anaphylaxis suffered from more severe tissue edema than other mice. Therefore, the inhibition of increased vascular permeability should be viewed as an important treatment strategy for anaphylaxis.
Epinephrine should be administered early to anaphylaxis patients because the delayed administration of epinephrine is associated with mortality. 33, 34 However, as far as we know, the current recommendation for early administration of epinephrine is based on retrospective studies 33, 34 or in vitro studies. 28 We demonstrated with in vivo data that the early use of epinephrine was vital for treating PAF-induced anaphylaxis. As time increased, epinephrine was progressively less effective in treating lethal-dose PAF-challenged mice and inhibiting PAFinduced tissue swelling. It was shown that epinephrine can inhibit the PAF release in the early stage of OVA-induced anaphylaxis, indicating the important inhibitory effect of epinephrine on the release of mediators from mast cells. It has been reported that aggregation of IgE-occupied Fc3RI can activate mast cells, resulting in the liberation of intracellular calcium and the release of proinammatory mediators from secretary granules, including PAF, histamine and leukotrienes. [35] [36] [37] Recently, it has been reported that stimulation of b 2 adrenergic receptors on mast cells can increase cytosolic cAMP level and activate cAMP-PKA signaling pathway, resulting in suppressing IgE/antigen-dependent signaling and calcium inux in mast cell degranulation. 38, 39 However, the detailed molecular mechanism responsible for the regulation of mast cell activation by b 2 adrenoceptor agonists remains to be studied further.
The currently recognized effects of epinephrine in treating anaphylaxis include vasoconstriction, cardiac inotropic effects and bronchodilation. 40 However, whether epinephrine contributes to the protection of vascular permeability during anaphylaxis is not well understood. Epinephrine was shown to stimulate the endothelium via b adrenergic receptors, which contribute to the maintenance of endothelial barrier properties under baseline conditions. 22 We demonstrated that epinephrine can alleviate endothelial barrier disruption under PAF-induced pathological conditions. PAF reduced TER of conuent HUVECs and induced the disintegration of VEcadherin staining. By contrast, epinephrine increased TER and enhanced linearized VE-cadherin distribution. Epinephrine presumably protects the endothelial barrier function by increasing intracellular cAMP levels. 22 In ischemia-reperfusion hyperpermeability, endothelial cells can be deactivated by the stimulation of cAMP production through cAMP-Epac-Rap1 signaling.
20 cAMP-Epac-Rap1 has been shown to promote the formation of VE-cadherin-based junctions. 41 Several studies have demonstrated that the phosphorylation of VE-cadherin tyrosine residues promotes its internalization, resulting in vascular hyperpermeability.
41,42
Vascular permeabilityincreasing factors such as VEGF, TNF or histamine, induce the phosphorylation of VE-cadherin at Y685, resulting in an increase in vascular permeability. 42 Wessel et al. generated knock-in mice expressing VE-cadherin mutants with the replacement of tyrosine by phenylalanine at position 685 (Y685F) and demonstrated that Y685 regulates vascular permeability. 43 Several studies have reported that PAF increases the phosphorylation of VE-cadherin tyrosine residues.
18, 44 Here, we rst demonstrated that PAF increased the phosphorylation of the Y658, Y685 and Y731 residues. Whether epinephrine protects VE-cadherin from being phosphorylated by vascular permeability-increasing factors such as PAF or histamine remains to be answered. Elucidation of the mechanisms that inuence the functions of VE-cadherin, which would allow the discovery of new specic targets, should be carried out.
The doses of PAF and epinephrine were selected according to published papers and our pilot study. 24, 25, 28 The intravenous injection of the 10 mg kg body wt À1 PAF can induce mild to moderate anaphylactic symptoms without resulting in the mortality of BALB/c mice, which was suitable for the measurement of tissue edema, rapid and profound drops in body temperature and blood pressure. However, this dose was not potent enough for the survival experiment since all the injected mice can survive. According to Macro's study, the LD 80 of PAF was 80 mg kg body wt À1 (i.v.) in Swiss mice. 24 We performed a pilot study with 4 BALB/c mice and found that this dose was lethal in 3 of 4 mice. Therefore, we selected a dose of 80 mg kg body wt À1 (i.v.) PAF in the survival experiment. For measuring the brain blood supply by LDLS, we adjusted PAF dose from 80 to 40 mg kg body wt À1 (i.v.), in order to keep the sufficient number of alive mice to complete the experiment. The dose of epinephrine was selected according to the veterinary formulary on the website of research animal resources of the University of Minnesota,
25
which noted that the dose of epinephrine is 0.2 mg kg body wt
À1
(i.v.) for treating anaphylaxis and 0.1 mg kg body wt À1 (i.v.) for cardiac resuscitation of mice. In our preliminary experiment, we found that mice intravenously injected with 0.2 mg kg body wt
epinephrine presented anxiety, restlessness and respiratory difficulty. Therefore, we decreased the dose of epinephrine and selected 0.1 mg kg body wt À1 (i.v.) as the dose for the experiments.
In the in vitro study, the concentration of PAF was extrapolated from the PAF dose of the survival study, and the concentration of epinephrine was chosen according to Peter's study. The ratio of the protein levels of VE-cadherin phosphorylated at Y658 to total VE-cadherin protein levels. (C) The ratio of the protein levels of phosphorylated VE-cadherin at Y685 to total VE-cadherin protein expression levels. (D) The ratio of the protein levels of VE-cadherin phosphorylated at Y731 to total VE-cadherin protein expression levels. Data are expressed as the mean AE SEM (n ¼ 3). *p < 0.05, **p < 0.01 compared with the control. If not marked, differences were not statistically significant.
